Probiotic for Graft-Versus-Host Disease After Stem Cell Transplant
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests whether a probiotic called Bacillus coagulans can help prevent or treat acute graft-versus-host disease, a common complication after donor stem cell transplants. It is for adults with blood cancers or severe aplastic anemia who received a specific type of transplant conditioning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have a blood cancer or severe aplastic anemia and received a stem cell transplant from a donor.
- Your transplant used high-dose chemotherapy (myeloablative conditioning).
- You are not allergic to Bacillus coagulans.
- You can take oral medication.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a special probiotic made from the patient's own gut bacteria and their donor's can help fix gut problems caused by a complication called graft-versus-host disease (aGVHD) after a stem cell transplant. It might help patients who are over 50 and scheduled for a specific type of transplant.
This trial tests whether giving a special type of immune-regulating cells (iMSCs) can help prevent a serious complication called graft-versus-host disease (GvHD) after a stem cell transplant. It’s for people who are at higher risk of developing GvHD based on a blood test taken a week or two after their transplant.
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
This trial studies a treatment made from donor gut microbes to help prevent a common complication after a transplant called acute graft-versus-host disease (aGVHD). It may help by improving the balance and variety of gut bacteria during recovery after haploidentical transplant.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a new way to prevent graft-versus-host disease (GvHD), a common complication after a stem cell transplant. It is for people with certain blood cancers who are getting a stem cell transplant from a half-matched family member or unrelated donor.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.